|
1
|
Piletič K and Kunej T: MicroRNA epigenetic
signatures in human disease. Arch Toxicol. 90:2405–2419. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sheikh AM, Small HY, Currie G and Delles
C: Systematic review of micro-RNA expression in pre-eclampsia
identifies a n number of common pathways associated with the
disease. PLoS One. 11:1–36. 2016. View Article : Google Scholar
|
|
3
|
Shao Y, Geng Y, Gu W, Huang J, Ning Z and
Pei H: Prognostic significance of microRNA-375 downregulation in
solid tumors: A meta-analysis. Dis Markers. 2014:6261852014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Isozaki Y, Hoshino I, Akutsu Y, Hanari N,
Mori M, Nishimori T, Murakami K, Akanuma N, Toyozumi T, Takahashi
M, et al: Screening of alternative drugs to the tumor suppressor
miR-375 in esophageal squamous cell carcinoma using the
connectivity map. Oncology. 87:351–363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu X, Ajani JA, Gu J, Chang DW, Tan W,
Hildebrandt MA, Huang M, Wang KK and Hawk E: MicroRNA expression
signatures during malignant progression from Barrett's esophagus to
esophageal adenocarcinoma. Cancer Prev Res (Phila). 6:196–205.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsukamoto Y, Nakada C, Noguchi T, Tanigawa
M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, et
al: MicroRNA-375 is downregulated in gastric carcinomas and
regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer
Res. 70:2339–2349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu AM, Poon RT and Luk JM: MicroRNA-375
targets Hippo-signaling effector YAP in liver cancer and inhibits
tumor properties. Biochem Biophys Res Commun. 394:623–627. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zaharie F, Muresan MS, Petrushev B, Berce
C, Gafencu GA, Selicean S, Jurj A, Cojocneanu-Petric R, Lisencu CI,
Pop LA, et al: Exosome-Carried microRNA-375 Inhibits Cell
Progression and Dissemination via Bcl-2 Blocking in Colon Cancer. J
Gastrointestin Liver Dis. 24:435–443. 2015.PubMed/NCBI
|
|
9
|
Zhou J, Song S, Cen J, Zhu D, Li D and
Zhang Z: MicroRNA-375 is downregulated in pancreatic cancer and
inhibits cell proliferation in vitro. Oncol Res. 20:197–203. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marchand L, Jalabert A, Meugnier E, Van
den Hende K, Fabien N, Nicolino M, Madec AM, Thivolet C and Rome S:
miRNA-375 a Sensor of Glucotoxicity Is Altered in the Serum of
Children with Newly Diagnosed Type 1 Diabetes. J Diabetes Res.
2016:18690822016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deiuliis JA: MicroRNAs as regulators of
metabolic disease: Pathophysiologic significance and emerging role
as biomarkers and therapeutics. Int J Obes. 40:88–101. 2016.
View Article : Google Scholar
|
|
12
|
Yamada H, Itoh M, Hiratsuka I and
Hashimoto S: Circulating microRNAs in autoimmune thyroid diseases.
Clin Endocrinol (Oxf). 81:276–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu TX and Rothenberg ME: Diagnostic,
functional, and therapeutic roles of microRNA in allergic diseases.
J Allergy Clin Immunol. 132:3–13; quiz 14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Torto-Alalibo T, Purwantini E, Lomax J,
Setubal JC, Mukhopadhyay B and Tyler BM: Genetic resources for
advanced biofuel production described with the Gene Ontology. Front
Microbiol. 5:5282014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Du J, Yuan Z, Ma Z, Song J, Xie X and Chen
Y: KEGG-PATH: Kyoto encyclopedia of genes and genomes-based pathway
analysis using a path analysis model. Mol Biosyst. 10:2441–2447.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Osako Y, Seki N, Kita Y, Yonemori K,
Koshizuka K, Kurozumi A, Omoto I, Sasaki K, Uchikado Y, Kurahara H,
et al: Regulation of MMP13 by antitumor microRNA-375 markedly
inhibits cancer cell migration and invasion in esophageal squamous
cell carcinoma. Int J Oncol. 49:2255–2264. 2016.PubMed/NCBI
|
|
17
|
Lian S, Park JS, Xia Y, Nguyen TT, Joo YE,
Kim KK, Kim HK and Jung YD: MicroRNA-375 functions as a
tumor-suppressor gene in gastric cancer by targeting recepteur
d'origine nantais. Int J Mol Sci. 17:E16332016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abdelmohsen K, Hutchison ER, Lee EK,
Kuwano Y, Kim MM, Masuda K, Srikantan S, Subaran SS, Marasa BS,
Mattson MP, et al: miR-375 inhibits differentiation of neurites by
lowering HuD levels. Mol Cell Biol. 30:4197–4210. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He Y, Jin J, Wang L, Hu Y, Liang D, Yang
H, Liu Y and Shan B: Evaluation of miR-21 and miR-375 as prognostic
biomarkers in oesophageal cancer in high-risk areas in China. Clin
Exp Metastasis. 34:73–84. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lew S and Chamberlain RS: Risk of
metabolic complications in patients with solid tumors treated with
mTOR inhibitors: Meta-analysis. Anticancer Res. 36:1711–1718.
2016.PubMed/NCBI
|
|
21
|
Chen H, Zhang K, Wu G, Song D, Chen K and
Yang H: Low expression of PHLPP1 in sacral chordoma and its
association with poor prognosis. Int J Clin Exp Pathol.
8:14741–14748. 2015.PubMed/NCBI
|
|
22
|
Walport LJ, Hopkinson RJ, Vollmar M,
Madden SK, Gileadi C, Oppermann U, Schofield CJ and Johansson C:
Human UTY(KDM6C) is a male-specific Nε-methyl lysyl demethylase. J
Biol Chem. 289:18302–18313. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang R, Langdon SP, Tse M, Mullen P, Um
IH, Faratian D and Harrison DJ: The role of HDAC2 in chromatin
remodelling and response to chemotherapy in ovarian cancer.
Oncotarget. 7:4695–4711. 2016.PubMed/NCBI
|
|
24
|
Katoh M and Katoh M: Identification and
characterization of FBXL19 gene in silico. Int J Mol
Med. 14:1109–1114. 2004.PubMed/NCBI
|
|
25
|
Garcia-Montero AC, Jara-Acevedo M,
Alvarez-Twose I, Teodosio C, Sanchez-Muñoz L, Muñiz C,
Muñoz-Gonzalez JI, Mayado A, Matito A, Caldas C, et al: KIT
D816V-mutated bone marrow mesenchymal stem cells in indolent
systemic mastocytosis are associated with disease progression.
Blood. 127:761–768. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ferrario CM, VonCannon J, Jiao Y, Ahmad S,
Bader M, Dell'Italia LJ, Groban L and Varagic J: Cardiac
angiotensin-(1–12) expression and systemic hypertension in rats
expressing the human angiotensinogen gene. Am J Physiol Heart Circ
Physiol. 310:H995–H1002. 2016.PubMed/NCBI
|
|
27
|
Cao W, Jin L, Zhou Z, Yang M, Wu C, Wu L
and Cui S: Overexpression of Intrarenal Renin-Angiotensin System in
Human Acute Tubular Necrosis. Kidney Blood Press Res. 41:746–756.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hume GE, Doecke JD, Huang N, Fowler EV,
Brown IS, Simms LA and Radford-Smith GL: Altered Expression of
Angiotensinogen and Mediators of Angiogenesis in Ileal Crohn's
Disease. J Gastrointestin Liver Dis. 25:39–48. 2016.PubMed/NCBI
|
|
29
|
Zhao S, Zhang X, Xu Y, Feng Y, Sheng W,
Cen J, Wu D and Han Y: Impact of JAK2V617F mutation burden on
disease phenotype in chinese patients with JAK2V617F-positive
polycythemia vera (PV) and essential thrombocythemia (ET). Int J
Med Sci. 13:85–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Twaroski K, Mallanna SK, Jing R, DiFurio
F, Urick A and Duncan SA: FGF2 mediates hepatic progenitor cell
formation during human pluripotent stem cell differentiation by
inducing the WNT antagonist NKD1. Genes Dev. 29:2463–2474. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pineda G, Shen Z, de Albuquerque CP,
Reynoso E, Chen J, Tu CC, Tang W, Briggs S, Zhou H and Wang JY:
Proteomics studies of the interactome of RNA polymerase II
C-terminal repeated domain. BMC Res Notes. 8:6162015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu TX, Lim EJ, Wen T, Plassard AJ, Hogan
SP, Martin LJ, Aronow BJ and Rothenberg ME: MiR-375 is
downregulated in epithelial cells after IL-13 stimulation and
regulates an IL-13-induced epithelial transcriptome. Mucosal
Immunol. 5:388–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liang W, Lai Y, Zhu M, Huang S, Feng W and
Gu X: Combretastatin A4 Regulates Proliferation, Migration,
Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt
Signaling Pathway. Med Sci Monit. 22:4911–4917. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Su W, Li S, Chen X, Yin L, Ma P, Ma Y and
Su B: GABARAPL1 suppresses metastasis by counteracting PI3K/Akt
pathway in prostate cancer. Oncotarget. 8:4449–4459.
2017.PubMed/NCBI
|
|
35
|
Chen H, Huang Y, Huang J, Lin L and Wei G:
Gigantol attenuates the proliferation of human liver cancer HepG2
cells through the PI3K/Akt/NF-κB signaling pathway. Oncol.
37:865–870. 2017.
|
|
36
|
Li F, Li L, Cheng M, Wang X, Hao J, Liu S
and Duan H: SHIP, a novel factor to ameliorate extracellular matrix
accumulation via suppressing PI3K/Akt/CTGF signaling in diabetic
kidney disease. Biochem Biophys Res Commun. 482:1477–1483. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang ZF, Pan ZY, Xu CS and Li ZQ:
Activation of G-protein coupled estrogen receptor 1 improves
early-onset cognitive impairment via PI3K/Akt pathway in rats with
traumatic brain injury. Biochem Biophys Res Commun. 482:948–953.
2017. View Article : Google Scholar : PubMed/NCBI
|
